
DERM Stock Forecast & Price Target
DERM Analyst Ratings
Bulls say
Journey Medical Corp has demonstrated significant growth in both payer access and prescriber adoption, with coverage of commercial lives increasing from approximately 30% in May to around 65% by July, impacting over 100 million lives. The number of prescribers utilizing Journey's products also reflects this momentum, escalating from about 660 in the first quarter to over 1,800 by the second quarter, indicating robust market traction. Furthermore, Journey’s established brand value, particularly for its product Accutane, enhances consumer loyalty and helps maintain its competitive market share in the dermatological sector.
Bears say
Journey Medical Corp faces a negative outlook primarily due to a significant decline in prescriptions for its flagship product, Accutane, dropping from 93,000 in Q1 2024 to approximately 66,000 in Q1 2025. The company also faces key challenges, including competitive pressures from both branded and generic rosacea treatments, uncertainty surrounding the uptake and reimbursement of its product Emrosi, and ongoing regulatory risks associated with its portfolio programs. Additionally, financial sustainability is threatened by potential cash burn exceeding current projections and the effectiveness of its sales force scaling efforts.
This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
DERM Analyst Forecast & Price Prediction
Start investing in DERM
Order type
Buy in
Order amount
Est. shares
0 shares